Minoxidil and Finasteride API Market by Type (Minoxidil API and Finasteride API), Disease Type (Minoxidil API [Alopecia Treatment and Hypertension] and Finasteride API [Alopecia Treatment, BPH Treatment, and Other]), Route of Administration (Topical, Oral, and Injectable), and Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast 2023– 2031
Minoxidil and Finasteride API Market Outlook
The global minoxidil and finasteride API market size was USD 153.4 Mn in 2022 and is likely to reach USD 262.9 Mn by 2031, expanding at a CAGR of 6.1% during 2023-2031. The market growth is attributed to the increasing cases of hair loss and the rising awareness regarding medications for hair loss treatment among patients globally.
Minoxidil (C9H15N5O) medications are available in two forms to treat various conditions. Minoxidil is taken orally to treat high blood pressure, and it is applied topically to treat hair loss and baldness. Finasteride is commonly prescribed to treat the symptoms of benign prostatic hyperplasia (BPH) and male pattern hair loss (androgenic alopecia). Finasteride's empirical formula is C23H36N2O2 and its molecular weight is 372.55 gms. Finasteride increases the number of scalp hairs in men who are experiencing hair loss.
Macro-economic Factors
Growing Demand for Alopecia Treatment
The growing geriatric population worldwide is one of the key factors boosting market growth as the aging population is mostly facing the issue of gradual thinning of hair. Improving healthcare infrastructure and increasing awareness about various effective therapies are the main factors pushing the demand for alopecia treatment.
COVID-19 Impact on Minoxidil and Finasteride API Market
The COVID-19 pandemic adversely impacted the global minoxidil and finasteride API market due to sudden disruption in the supply chain, which resulted in a harsh financial impact on industries and financial markets. Manufacturers of minoxidil and finasteride API were impacted during the pandemic, due to restrictions and the closure of global industries. Due to global transportation restrictions, raw material import and export were severely hampered.
Following COVID-19, it is expected that high R&D expenditure in Minoxidil and Finasteride API will fuel the market in the near future. Increasing support from various governments and environmentalists through investments in the manufacture of Minoxidil and Finasteride API, on the other hand, is expected to fuel the market following the pandemic.
Minoxidil and Finasteride API Market Dynamics
Drivers
- Increasing demand for alopecia treatments
The rapid growth in the number of alopecia patients with significant hair loss can increase the use of minoxidil and finasteride APIs. Alopecia areata disease happens when an immune system attacks hair follicles and causes hair loss. As per the American Hair Loss Association (AHLA), more than 90% of hair loss is caused by Androgenetic Alopecia and also around 32 million men and 20 million women above the 35 age group are suffering from hair loss which is increasing the demand for alopecia treatments.
- Pattern Hair Loss in Men and Women
Rising health issues such as cancer, hypertension, depression, arthritis, and cardiovascular diseases and to cure these diseases, patients need specific medication dosages which in turn results in significant hair loss. During, the cancer treatment process, especially in chemotherapy patients lose a significant amount of hair. Increasing demand for Minoxidil oil and medication as it helps patients with hair regrowth and nourishment which drives the global market.
Restraints
- Side effects of Minoxidil and Finasteride
Minoxidil is a widely used popular and highly medication, and it has a number of side effects that can hamper the global market. Minoxidil and Finasteride treatment is expensive compared to other types of treatment and skin irritation near or at the application site is the most common side effect of minoxidil. Minoxidil skin irritation can cause itching and scale in some people. These factors are expected to hinder market growth.
Opportunities
- Growing consumer spending on hair care products
The rising trend of maintaining long hair among men and the adoption of multiple hairstyles has resulted in an increase in the consumption of hair styling products that can create lucrative opportunities for the market during the forecast period. Increasing awareness about hair care among men & women and the rising adoption of hair care and styling products are expected to contribute to the growth of the market.
Scope of Minoxidil and Finasteride API Market Report
The report on the global Minoxidil and Finasteride API market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.
Attributes |
Details |
Report Title |
Minoxidil and Finasteride API Market – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast |
Base Year |
2022 |
Historic Data |
2020–2021 |
Forecast Period |
2023–2031 |
Segmentation |
Disease Type (Minoxidil API (Alopecia treatment and Hypertension), Finasteride API (Alopecia treatment, BPH treatment, and Other)), and Route of Administration (Topical, Oral, and Injectable) |
Regional Scope |
Regions (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) |
Report Coverage |
Company Share, Minoxidil and Finasteride API Market Size and Analysis, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast |
Key Players Covered |
Dr. Reddy’s Laboratories Ltd; Global Calcium PVT LTD; Global Pharma; Samex Overseas; Ralington Pharma; ICROM; Beloor Bayir; Flamma Group; SynZeal Research Pvt; Curia global; Tiefenbacher API + Ingredients; and Taj Pharmaceuticals |
Minoxidil and Finasteride API Market Segmental Outlook
Why is the Minoxidil API More Prevalent than the Finasteride API?
On the basis of type, the market is bifurcated into a Minoxidil API and Finasteride API. The Minoxidil API segment holds a significant share of the market during the forecast period as it is safe for use for both men and women for the treatment of alopecia. Minoxidil helps slow the progress of hair loss and promotes the regrowth of lost hair and it is widely used as one of the most effective treatments for hair loss and baldness which can further boost the demand for Minoxidil API.
The Finasteride API segment is expected to register a considerable CAGR during the forecast period owing to the increasing benign prostatic hyperplasia in men and Finasteride API is widely used to cure the disease. It is a medication used to treat pattern hair loss disease in men which is known as androgenetic alopecia.
In men with pattern hair loss, the balding scalp contains increased amounts of DHT and miniaturized hair follicles compared with the hairy scalp. Finasteride API decreases the scalp and DHT concentration in androgenetic alopecia patients. It is taken by mouth and can be used to treat excessive hair growth in women.
Based on disease type, the market is fragmented into Minoxidil API (Alopecia treatment, Hypertension), Finasteride API (Alopecia treatment, BPH treatment, Other). The Minoxidil API segment is held a substantial share of the market, owing to the growing demand for hair loss and hypertension treatments.
In terms of the Route of Administration, the market is fragmented into topical, oral, and injectable. The topical category held a considerable share of the market over the forecast period, due as it is easy to apply and is completely non-invasive in nature.
Minoxidil and Finasteride API Market Regional Outlook
The global minoxidil and finasteride API Market is expected to maintain its dominance over the forecast period as a result of the rising API production landscape in developing economies such as China and India, which is expected to positively impact market growth.
The rising prevalence of BPH (benign prostatic hyperplasia) due to an aging population is projected to drive the market in this region. The market in Europe is expected to grow at a rapid pace due to the increasing use of non-invasive treatment, which is anticipated to support the demand for minoxidil and finasteride.
Key Benefits for Industry Participants & Stakeholders
- In-depth Analysis of the Global Minoxidil and Finasteride API Market
- Historical, Current, and Projected Market Size in terms of Value
- Potential & Niche Segments and Regions Exhibiting Promising Growth Covered
- Industry Drivers, Restraints, and Opportunities Covered in the Study
- Recent Industry Trends and Developments
- Competitive Landscape & Strategies of Key Players
- Neutral Perspective on Global Minoxidil and Finasteride API Market Performance
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Minoxidil and Finasteride API Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Minoxidil and Finasteride API Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Minoxidil and Finasteride API Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Minoxidil and Finasteride API Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Minoxidil and Finasteride API Market Size & Forecast, 2015-2030
4.5.1 Minoxidil and Finasteride API Market Size and Y-o-Y Growth
4.5.2 Minoxidil and Finasteride API Market Absolute $ Opportunity
Chapter 5 Global Minoxidil and Finasteride API Market Analysis and Forecast By Types
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities By Types
5.1.2 Basis Point Share (BPS) Analysis By Types
5.1.3 Absolute $ Opportunity Assessment By Types
5.2 Minoxidil and Finasteride API Market Size Forecast By Types
5.2.1 Minoxidil API
5.2.2 Finasteride API
5.3 Market Attractiveness Analysis By Types
Chapter 6 Global Minoxidil and Finasteride API Market Analysis and Forecast By Disease Type
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities By Disease Type
6.1.2 Basis Point Share (BPS) Analysis By Disease Type
6.1.3 Absolute $ Opportunity Assessment By Disease Type
6.2 Minoxidil and Finasteride API Market Size Forecast By Disease Type
6.2.1 Minoxidil API
6.2.1.1 Alopecia treatment
6.2.1.2 Hypertension
6.2.2 Finasteride API
6.2.2.1 Alopecia treatment
6.2.2.2 BPH treatment
6.2.2.3 Other
6.3 Market Attractiveness Analysis By Disease Type
Chapter 7 Global Minoxidil and Finasteride API Market Analysis and Forecast By Route of Administration
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities By Route of Administration
7.1.2 Basis Point Share (BPS) Analysis By Route of Administration
7.1.3 Absolute $ Opportunity Assessment By Route of Administration
7.2 Minoxidil and Finasteride API Market Size Forecast By Route of Administration
7.2.1 Topical
7.2.2 Oral
7.2.3 Injectable
7.3 Market Attractiveness Analysis By Route of Administration
Chapter 8 Global Minoxidil and Finasteride API Market Analysis and Forecast by Region
8.1 Introduction
8.1.1 Key Market Trends & Growth Opportunities by Region
8.1.2 Basis Point Share (BPS) Analysis by Region
8.1.3 Absolute $ Opportunity Assessment by Region
8.2 Minoxidil and Finasteride API Market Size Forecast by Region
8.2.1 North America
8.2.2 Europe
8.2.3 Asia Pacific
8.2.4 Latin America
8.2.5 Middle East & Africa (MEA)
8.3 Market Attractiveness Analysis by Region
Chapter 9 Coronavirus Disease (COVID-19) Impact
9.1 Introduction
9.2 Current & Future Impact Analysis
9.3 Economic Impact Analysis
9.4 Government Policies
9.5 Investment Scenario
Chapter 10 North America Minoxidil and Finasteride API Analysis and Forecast
10.1 Introduction
10.2 North America Minoxidil and Finasteride API Market Size Forecast by Country
10.2.1 U.S.
10.2.2 Canada
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 North America Minoxidil and Finasteride API Market Size Forecast By Types
10.6.1 Minoxidil API
10.6.2 Finasteride API
10.7 Basis Point Share (BPS) Analysis By Types
10.8 Absolute $ Opportunity Assessment By Types
10.9 Market Attractiveness Analysis By Types
10.10 North America Minoxidil and Finasteride API Market Size Forecast By Disease Type
10.10.1 Minoxidil API
10.10.1.1 Alopecia treatment
10.10.1.2 Hypertension
10.10.2 Finasteride API
10.10.2.1 Alopecia treatment
10.10.2.2 BPH treatment
10.10.2.3 Other
10.11 Basis Point Share (BPS) Analysis By Disease Type
10.12 Absolute $ Opportunity Assessment By Disease Type
10.13 Market Attractiveness Analysis By Disease Type
10.14 North America Minoxidil and Finasteride API Market Size Forecast By Route of Administration
10.14.1 Topical
10.14.2 Oral
10.14.3 Injectable
10.15 Basis Point Share (BPS) Analysis By Route of Administration
10.16 Absolute $ Opportunity Assessment By Route of Administration
10.17 Market Attractiveness Analysis By Route of Administration
Chapter 11 Europe Minoxidil and Finasteride API Analysis and Forecast
11.1 Introduction
11.2 Europe Minoxidil and Finasteride API Market Size Forecast by Country
11.2.1 Germany
11.2.2 France
11.2.3 Italy
11.2.4 U.K.
11.2.5 Spain
11.2.6 Russia
11.2.7 Rest of Europe
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Europe Minoxidil and Finasteride API Market Size Forecast By Types
11.6.1 Minoxidil API
11.6.2 Finasteride API
11.7 Basis Point Share (BPS) Analysis By Types
11.8 Absolute $ Opportunity Assessment By Types
11.9 Market Attractiveness Analysis By Types
11.10 Europe Minoxidil and Finasteride API Market Size Forecast By Disease Type
11.10.1 Minoxidil API
11.10.1.1 Alopecia treatment
11.10.1.2 Hypertension
11.10.2 Finasteride API
11.10.2.1 Alopecia treatment
11.10.2.2 BPH treatment
11.10.2.3 Other
11.11 Basis Point Share (BPS) Analysis By Disease Type
11.12 Absolute $ Opportunity Assessment By Disease Type
11.13 Market Attractiveness Analysis By Disease Type
11.14 Europe Minoxidil and Finasteride API Market Size Forecast By Route of Administration
11.14.1 Topical
11.14.2 Oral
11.14.3 Injectable
11.15 Basis Point Share (BPS) Analysis By Route of Administration
11.16 Absolute $ Opportunity Assessment By Route of Administration
11.17 Market Attractiveness Analysis By Route of Administration
Chapter 12 Asia Pacific Minoxidil and Finasteride API Analysis and Forecast
12.1 Introduction
12.2 Asia Pacific Minoxidil and Finasteride API Market Size Forecast by Country
12.2.1 China
12.2.2 Japan
12.2.3 South Korea
12.2.4 India
12.2.5 Australia
12.2.6 South East Asia (SEA)
12.2.7 Rest of Asia Pacific (APAC)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Asia Pacific Minoxidil and Finasteride API Market Size Forecast By Types
12.6.1 Minoxidil API
12.6.2 Finasteride API
12.7 Basis Point Share (BPS) Analysis By Types
12.8 Absolute $ Opportunity Assessment By Types
12.9 Market Attractiveness Analysis By Types
12.10 Asia Pacific Minoxidil and Finasteride API Market Size Forecast By Disease Type
12.10.1 Minoxidil API
12.10.1.1 Alopecia treatment
12.10.1.2 Hypertension
12.10.2 Finasteride API
12.10.2.1 Alopecia treatment
12.10.2.2 BPH treatment
12.10.2.3 Other
12.11 Basis Point Share (BPS) Analysis By Disease Type
12.12 Absolute $ Opportunity Assessment By Disease Type
12.13 Market Attractiveness Analysis By Disease Type
12.14 Asia Pacific Minoxidil and Finasteride API Market Size Forecast By Route of Administration
12.14.1 Topical
12.14.2 Oral
12.14.3 Injectable
12.15 Basis Point Share (BPS) Analysis By Route of Administration
12.16 Absolute $ Opportunity Assessment By Route of Administration
12.17 Market Attractiveness Analysis By Route of Administration
Chapter 13 Latin America Minoxidil and Finasteride API Analysis and Forecast
13.1 Introduction
13.2 Latin America Minoxidil and Finasteride API Market Size Forecast by Country
13.2.1 Brazil
13.2.2 Mexico
13.2.3 Rest of Latin America (LATAM)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Latin America Minoxidil and Finasteride API Market Size Forecast By Types
13.6.1 Minoxidil API
13.6.2 Finasteride API
13.7 Basis Point Share (BPS) Analysis By Types
13.8 Absolute $ Opportunity Assessment By Types
13.9 Market Attractiveness Analysis By Types
13.10 Latin America Minoxidil and Finasteride API Market Size Forecast By Disease Type
13.10.1 Minoxidil API
13.10.1.1 Alopecia treatment
13.10.1.2 Hypertension
13.10.2 Finasteride API
13.10.2.1 Alopecia treatment
13.10.2.2 BPH treatment
13.10.2.3 Other
13.11 Basis Point Share (BPS) Analysis By Disease Type
13.12 Absolute $ Opportunity Assessment By Disease Type
13.13 Market Attractiveness Analysis By Disease Type
13.14 Latin America Minoxidil and Finasteride API Market Size Forecast By Route of Administration
13.14.1 Topical
13.14.2 Oral
13.14.3 Injectable
13.15 Basis Point Share (BPS) Analysis By Route of Administration
13.16 Absolute $ Opportunity Assessment By Route of Administration
13.17 Market Attractiveness Analysis By Route of Administration
Chapter 14 Middle East & Africa (MEA) Minoxidil and Finasteride API Analysis and Forecast
14.1 Introduction
14.2 Middle East & Africa (MEA) Minoxidil and Finasteride API Market Size Forecast by Country
14.2.1 Saudi Arabia
14.2.2 South Africa
14.2.3 UAE
14.2.4 Rest of Middle East & Africa (MEA)
14.3 Basis Point Share (BPS) Analysis by Country
14.4 Absolute $ Opportunity Assessment by Country
14.5 Market Attractiveness Analysis by Country
14.6 Middle East & Africa (MEA) Minoxidil and Finasteride API Market Size Forecast By Types
14.6.1 Minoxidil API
14.6.2 Finasteride API
14.7 Basis Point Share (BPS) Analysis By Types
14.8 Absolute $ Opportunity Assessment By Types
14.9 Market Attractiveness Analysis By Types
14.10 Middle East & Africa (MEA) Minoxidil and Finasteride API Market Size Forecast By Disease Type
14.10.1 Minoxidil API
14.10.1.1 Alopecia treatment
14.10.1.2 Hypertension
14.10.2 Finasteride API
14.10.2.1 Alopecia treatment
14.10.2.2 BPH treatment
14.10.2.3 Other
14.11 Basis Point Share (BPS) Analysis By Disease Type
14.12 Absolute $ Opportunity Assessment By Disease Type
14.13 Market Attractiveness Analysis By Disease Type
14.14 Middle East & Africa (MEA) Minoxidil and Finasteride API Market Size Forecast By Route of Administration
14.14.1 Topical
14.14.2 Oral
14.14.3 Injectable
14.15 Basis Point Share (BPS) Analysis By Route of Administration
14.16 Absolute $ Opportunity Assessment By Route of Administration
14.17 Market Attractiveness Analysis By Route of Administration
Chapter 15 Competition Landscape
15.1 Minoxidil and Finasteride API Market: Competitive Dashboard
15.2 Global Minoxidil and Finasteride API Market: Market Share Analysis, 2021
15.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
15.3.1 Dr. Reddy’s Laboratories Ltd
15.3.2 Global Calcium PVT LTD
15.3.3 Global Pharma
15.3.4 Samex Overseas
15.3.5 Ralington Pharma
15.3.6 ICROM
15.3.7 Beloor Bayir
15.3.8 Flamma Group
15.3.9 SynZeal Research Pvt
15.3.10 Curia global
15.3.11 Tiefenbacher API + Ingredients
15.3.12 Taj Pharmaceuticals